Identification of bacterial biofilm and the Staphylococcus aureus derived protease, staphopain, on the skin surface of patients with atopic dermatitis

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Sonesson, Andreas ^a,b   Przybyszewska, Kornelia ^a,c,i   Eriksson, Sigrid ^a,b   Mörgelin, Matthias ^d   Kjellström, Sven ^e   Davies, Julia ^f   Potempa, Jan ^c,g   Schmidtchen, Artur ^a,b,h  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c JAGIELLONIAN UNIVERSITY   (Poland)

^d LUND UNIVERSITY   (Sweden)

^e LUND UNIVERSITY   (Sweden)

^f MALMÖ UNIVERSITY   (Sweden)

^g UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

^h NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

ⁱ QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTIMICROBIAL PEPTIDE LL-37; CATHELICIDIN; CYSTEINE PROTEINASE; PEPTIDE FRAGMENT; STAPHOPAIN B PROTEIN, STAPHYLOCOCCUS AUREUS;

ADULT; AMINO ACID SEQUENCE; ATOPIC DERMATITIS; BIOFILM; CHEMISTRY; DRUG EFFECT; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOLOGY; PHYSIOLOGY; SKIN; STAPHYLOCOCCUS AUREUS; ULTRASTRUCTURE;

ADULT; AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; BIOFILMS; CATHELICIDINS; CYSTEINE ENDOPEPTIDASES; DERMATITIS, ATOPIC; HUMANS; MICROBIAL SENSITIVITY TESTS; PEPTIDE FRAGMENTS; SKIN; STAPHYLOCOCCUS AUREUS;

EID: 85027838321     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-08046-2     Document Type: Article

References (67)

1. Bieber, T. Atopic dermatitis. Ann Dermatol 22, 125-137, doi:10.5021/ad.2010.22.2.125 (2010).
2. Weidinger, S. & Novak, N. Atopic dermatitis. Lancet 387, 1109-1122, doi:10.1016/S0140-6736(15)00149-X (2016).
3. Wanke, I. et al. Staphylococcus aureus skin colonization is promoted by barrier disruption and leads to local inflammation. Exp Dermatol 22, 153-155, doi:10.1111/exd.12083 (2013).
4. Jinnestal, C. L., Belfrage, E., Back, O., Schmidtchen, A. & Sonesson, A. Skin barrier impairment correlates with cutaneous Staphylococcus aureus colonization and sensitization to skin-associated microbial antigens in adult patients with atopic dermatitis. Int J Dermatol 53, 27-33, doi:10.1111/ijd.12198 (2014).
5. Maintz, L. & Novak, N. Modifications of the innate immune system in atopic dermatitis. J Innate Immun 3, 131-141, doi:10.1159/000323963 (2011).
6. Archer, N. K. et al. Staphylococcus aureus biofilms: properties, regulation, and roles in human disease. Virulence 2, 445-459, doi:10.4161/viru.2.5.17724 (2011).
7. Allen, H. B. et al. The presence and impact of biofilm-producing staphylococci in atopic dermatitis. JAMA dermatology 150, 260-265, doi:10.1001/jamadermatol.2013.8627 (2014).
8. Vlassova, N., Han, A., Zenilman, J. M., James, G. & Lazarus, G. S. New horizons for cutaneous microbiology: the role of biofilms in dermatological disease. Br J Dermatol 165, 751-759, doi:10.1111/j.1365-2133.2011.10458.x (2011).
9. Eriksson, S., van der Plas, M. J., Morgelin, M. & Sonesson, A. Antibacterial and anti-biofilm effects of sodium hypochlorite against Staphylococcus aureus isolates derived from patients with atopic dermatitis. Br J Dermatol, doi:10.1111/bjd.15410 (2017).
10. Otto, M. Staphylococcal infections: mechanisms of biofilm maturation and detachment as critical determinants of pathogenicity. Annual review of medicine 64, 175-188, doi:10.1146/annurev-med-042711-140023 (2013).
11. Joo, H. S. & Otto, M. Mechanisms of resistance to antimicrobial peptides in staphylococci. Biochim Biophys Acta 1848, 3055-3061, doi:10.1016/j.bbamem.2015.02.009 (2015).
12. Vuong, C. et al. Polysaccharide intercellular adhesin (PIA) protects Staphylococcus epidermidis against major components of the human innate immune system. Cell Microbiol 6, 269-275 (2004).
13. Harder, J., Schroder, J. M. & Glaser, R. The skin surface as antimicrobial barrier: present concepts and future outlooks. Exp Dermatol 22, 1-5, doi:10.1111/exd.12046 (2013).
14. Biedermann, T. Dissecting the role of infections in atopic dermatitis. Acta Derm Venereol 86, 99-109 (2006).
15. Zasloff, M. Antimicrobial peptides of multicellular organisms. Nature 415, 389-395, doi:10.1038/415389a415389a (2002).
16. Reinholz, M., Ruzicka, T. & Schauber, J. Cathelicidin LL-37: an antimicrobial peptide with a role in inflammatory skin disease. Ann Dermatol 24, 126-135, doi:10.5021/ad.2012.24.2.126 (2012).
17. Murakami, M. et al. Cathelicidin anti-microbial peptide expression in sweat, an innate defense system for the skin. J Invest Dermatol 119, 1090-1095, doi:10.1046/j.1523-1747.2002.19507.x (2002).
18. Yamasaki, K. et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 13, 975-980, doi:10.1038/nm1616 (2007).
19. Sieprawska-Lupa, M. et al. Degradation of human antimicrobial peptide LL-37 by Staphylococcus aureus-derived proteinases. Antimicrob Agents Chemother 48, 4673-4679 (2004).
20. Shaw, L., Golonka, E., Potempa, J. & Foster, S. J. The role and regulation of the extracellular proteases of Staphylococcus aureus. Microbiology 150, 217-228, doi:10.1099/mic.0.26634-0 (2004).
21. Miedzobrodzki, J., Kaszycki, P., Bialecka, A. & Kasprowicz, A. Proteolytic activity of Staphylococcus aureus strains isolated from the colonized skin of patients with acute-phase atopic dermatitis. European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology 21, 269-276, doi:10.1007/s10096-002-0706-4 (2002).
22. Marques, V. F. et al. Biofilm production and beta-lactamic resistance in Brazilian Staphylococcus aureus isolates from bovine mastitis. Braz J Microbiol 48, 118-124, doi:10.1016/j.bjm.2016.10.001 (2017).
23. Braff, M. H. et al. Structure-function relationships among human cathelicidin peptides: dissociation of antimicrobial properties from host immunostimulatory activities. J Immunol 174, 4271-4278 (2005).
24. Sigurdardottir, T. et al. In silico identification and biological evaluation of antimicrobial peptides based on human cathelicidin LL-37. Antimicrob Agents Chemother 50, 2983-2989, doi:10.1128/AAC.01583-05 (2006).
25. Murakami, M., Lopez-Garcia, B., Braff, M., Dorschner, R. A. & Gallo, R. L. Postsecretory processing generates multiple cathelicidins for enhanced topical antimicrobial defense. J Immunol 172, 3070-3077 (2004).
26. Morizane, S. et al. Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands. J Invest Dermatol 132, 135-143, doi:10.1038/jid.2011.259 (2012).
27. Molhoek, E. M. et al. Structure-function relationship of the human antimicrobial peptide LL-37 and LL-37 fragments in the modulation of TLR responses. Biological chemistry 390, 295-303, doi:10.1515/BC.2009.037 (2009).
28. Choi, K. Y., Napper, S. & Mookherjee, N. Human cathelicidin LL-37 and its derivative IG-19 regulate interleukin-32-induced inflammation. Immunology 143, 68-80, doi:10.1111/imm.12291 (2014).
29. Ciornei, C. D., Sigurdardottir, T., Schmidtchen, A. & Bodelsson, M. Antimicrobial and chemoattractant activity, lipopolysaccharide neutralization, cytotoxicity, and inhibition by serum of analogs of human cathelicidin LL-37. Antimicrob Agents Chemother 49, 2845-2850, doi:10.1128/AAC.49.7.2845-2850.2005 (2005).
30. Jerala, R. Structural biology of the LPS recognition. International journal of medical microbiology: IJMM 297, 353-363, doi:10.1016/j. ijmm.2007.04.001 (2007).
31. Takeda, K. & Akira, S. TLR signaling pathways. Seminars in immunology 16, 3-9 (2004).
32. Yamasaki, K. et al. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. Faseb J 20, 2068-2080 (2006).
33. Hell, E., Giske, C. G., Nelson, A., Romling, U. & Marchini, G. Human cathelicidin peptide LL37 inhibits both attachment capability and biof ilm formation of Staphylococcus epidermidis. Letters in applied microbiology 50, 211-215, doi:10.1111/j.1472-765X.2009.02778.x (2010).
34. Akiyama, H. et al. Confocal laser scanning microscopic observation of glycocalyx production by Staphylococcus aureus in skin lesions of bullous impetigo, atopic dermatitis and pemphigus foliaceus. Br J Dermatol 148, 526-532 (2003).
35. Jones, R. C., Deck, J., Edmondson, R. D. & Hart, M. E. Relative quantitative comparisons of the extracellular protein profiles of Staphylococcus aureus UAMS-1 and its sarA, agr, and sarA agr regulatory mutants using one-dimensional polyacrylamide gel electrophoresis and nanocapillary liquid chromatography coupled with tandem mass spectrometry. J Bacteriol 190, 5265-5278, doi:10.1128/JB.00383-08 (2008).
36. Frohm, M. et al. The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J Biol Chem 272, 15258-15263 (1997).
37. Sorensen, O. E. et al. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 97, 3951-3959 (2001).
38. Sorensen, O., Cowland, J. B., Askaa, J. & Borregaard, N. An ELISA for hCAP-18, the cathelicidin present in human neutrophils and plasma. J Immunol Methods 206, 53-59 (1997).
39. Le, K. Y., Dastgheyb, S., Ho, T. V. & Otto, M. Molecular determinants of staphylococcal biofilm dispersal and structuring. Frontiers in cellular and infection microbiology 4, 167, doi:10.3389/fcimb.2014.00167 (2014).
40. Haisma, E. M. et al. LL-37-derived peptides eradicate multidrug-resistant Staphylococcus aureus from thermally wounded human skin equivalents. Antimicrob Agents Chemother 58, 4411-4419, doi:10.1128/AAC.02554-14 (2014).
41. Mishra, B., Golla, R. M., Lau, K., Lushnikova, T. & Wang, G. Anti-Staphylococcal Biofilm Effects of Human Cathelicidin Peptides. ACS Med Chem Lett 7, 117-121, doi:10.1021/acsmedchemlett.5b00433 (2016).
42. Wang, G., Mishra, B., Epand, R. F. & Epand, R. M. High-quality 3D structures shine light on antibacterial, anti-biofilm and antiviral activities of human cathelicidin LL-37 and its fragments. Biochim Biophys Acta 1838, 2160-2172, doi:10.1016/j.bbamem.2014.01.016 (2014).
43. Boguniewicz, M. & Leung, D. Y. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev 242, 233-246, doi:10.1111/j.1600-065X.2011.01027.x (2011).
44. Meyer-Hoffert, U. & Schroder, J. M. Epidermal proteases in the pathogenesis of rosacea. J Investig Dermatol Symp Proc 15, 16-23, doi:10.1038/jidsymp.2011.2 (2011).
45. Takai, T. & Ikeda, S. Barrier dysfunction caused by environmental proteases in the pathogenesis of allergic diseases. Allergol Int 60, 25-35, doi:10.2332/allergolint.10-RAI-0273 (2011).
46. Niebuhr, M., Heratizadeh, A., Wichmann, K., Satzger, I. & Werfel, T. Intrinsic alterations of pro-inflammatory mediators in unstimulated and TLR-2 stimulated keratinocytes from atopic dermatitis patients. Exp Dermatol 20, 468-472, doi:10.1111/j.1600-0625.2011.01277.x (2011).
47. Olaru, F. & Jensen, L. E. Staphylococcus aureus stimulates neutrophil targeting chemokine expression in keratinocytes through an autocrine IL-1alpha signaling loop. J Invest Dermatol 130, 1866-1876, doi:10.1038/jid.2010.37 (2010).
48. Taskapan, M. O. & Kumar, P. Role of staphylococcal superantigens in atopic dermatitis: from colonization to inflammation. Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology 84, 3-10; quiz 11-12, doi:10.1016/S1081-1206(10)62731-7 (2000).
49. Hirasawa, Y. et al. Staphylococcus aureus extracellular protease causes epidermal barrier dysfunction. J Invest Dermatol 130, 614-617, doi:10.1038/jid.2009.257 (2010).
50. Watters, C., Fleming, D., Bishop, D. & Rumbaugh, K. P. Host Responses to Biofilm. Prog Mol Biol Transl Sci 142, 193-239, doi:10.1016/bs.pmbts.2016.05.007 (2016).
51. Prabhakara, R. et al. Suppression of the inflammatory immune response prevents the development of chronic biofilm infection due to methicillin-resistant Staphylococcus aureus. Infect Immun 79, 5010-5018, doi:10.1128/IAI.05571-11 (2011).
52. Mootz, J. M., Malone, C. L., Shaw, L. N. & Horswill, A. R. Staphopains modulate Staphylococcus aureus biofilm integrity. Infect Immun 81, 3227-3238, doi:10.1128/IAI.00377-13 (2013).
53. Brenninkmeijer, E. E., Schram, M. E., Leeflang, M. M., Bos, J. D. & Spuls, P. I. Diagnostic criteria for atopic dermatitis: a systematic review. Br J Dermatol 158, 754-765, doi:10.1111/j.1365-2133.2007.08412.x (2008).
54. Williams, H. C. et al. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol 131, 383-396 (1994).
55. Williamson, P. & Kligman, A. M. A new method for the quantitative investigation of cutaneous bacteria. J Invest Dermatol 45, 498-503 (1965).
56. Baranska-Rybak, W., Sonesson, A., Nowicki, R. & Schmidtchen, A. Glycosaminoglycans inhibit the antibacterial activity of LL-37 in biological fluids. J Antimicrob Chemother 57, 260-265, doi:10.1093/jac/dki460 (2006).
57. Masny, A. & Plucienniczak, A. Fingerprinting of bacterial genomes by amplification of DNA fragments surrounding rare restriction sites. Biotechniques 31(930-934), 936 (2001).
58. van der Plas, M. J. et al. Maggot excretions/secretions are differentially effective against biofilms of Staphylococcus aureus and Pseudomonas aeruginosa. J Antimicrob Chemother 61, 117-122, doi:10.1093/jac/dkm407 (2008).
59. Ceri, H. et al. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. Journal of clinical microbiology 37, 1771-1776 (1999).
60. Wiegand, I., Hilpert, K. & Hancock, R. E. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc 3, 163-175 (2008).
61. Andersson, E. et al. Antimicrobial activities of heparin-binding peptides. Eur J Biochem 271, 1219-1226, doi:4035 [pii] (2004).
62. Lehrer, R. I., Rosenman, M., Harwig, S. S., Jackson, R. & Eisenhauer, P. Ultrasensitive assays for endogenous antimicrobial polypeptides. J Immunol Methods 137, 167-173, doi:0022-1759(91)90021-7 [pii] (1991).
63. Bengtson, S. H., Eddleston, J., Morgelin, M., Zuraw, B. L. & Herwald, H. Regulation of kinin B(2) receptors by bradykinin in human lung cells. Biological chemistry 389, 1435-1440, doi:10.1515/BC.2008.159 (2008).
64. Potempa, J., Dubin, A., Korzus, G. & Travis, J. Degradation of elastin by a cysteine proteinase from Staphylococcus aureus. J Biol Chem 263, 2664-2667 (1988).
65. Rzychon, M., Sabat, A., Kosowska, K., Potempa, J. & Dubin, A. Staphostatins: an expanding new group of proteinase inhibitors with a unique specificity for the regulation of staphopains, Staphylococcus spp. cysteine proteinases. Mol Microbiol 49, 1051-1066 (2003).
66. Filipek, R. et al. The Staphostatin-staphopain complex: a forward binding inhibitor in complex with its target cysteine protease. J Biol Chem 278, 40959-40966, doi:10.1074/jbc.M302926200 (2003).
67. Kjellstrom, S. & Jensen, O. N. Phosphoric acid as a matrix additive for MALDI MS analysis of phosphopeptides and phosphoproteins. Analytical chemistry 76, 5109-5117, doi:10.1021/ac0400257 (2004).